Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Morgan Sindall makes 'positive start' to FY24

(Sharecast News) - Construction firm Morgan Sindall said on Thursday that it has made a "positive start to the year" and that the group was trading in line with expectations. Morgan Sindall said partnership housing profits remained in line with previous guidance, with sales activity across both mixed-tenure and contracting continuing to show good improvement, while mixed use partnerships was also expected to be in line with previous guidance, as it continues to convert "a number of sizeable opportunities" into preferred bidder schemes, while also securing two signed development agreements in the period to date.

The FTSE 250-listed firm also said its fit out division continued to benefit from "a very strong trading momentum" and was expected to exceed the top-end of its revised medium term targets of £60.0m-£85.0m, and its property services wing remained on track to deliver "a modest profit" for the year, following the successful completion of its remediation programme in 2024.

Morgan Sindall added that its total secured order book sat at £11.3bn on 31 March, broadly in line with the year-end position of £11.4bn and up 26% year-on-year.

Chief executive John Morgan said: "Since the start of the year, trading has been better than we originally expected and looking ahead to the rest of the year, our high-quality secured order book gives us strong confidence of delivering a full year performance in line with our current expectations."

As of 1020 BST, Morgan Sindall shares were up 0.14% at 3,540.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.